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Neurological and psychiatric (mental health) disorders have a large impact on health burden globally. 
Cognitive disorders (including dementia) and stroke are leading causes of disability. Mental health 
disorders including depression contribute up to one third of total years lived with disability. The 
Neurological and mental health Global Epidemiology Network (NeuroGEN) is an international multi-
database network that harnesses administrative and electronic medical records from Australia, Asia, 
Europe and North America. Using these databases NeuroGEN will investigate medication use and 
health outcomes in neurological and mental health disorders. A key objective of NeuroGEN is to 
facilitate high-quality observational studies to address evidence-practice gaps where randomized 
controlled trials do not provide sufficient information on medication benefits and risks that is specific 
to vulnerable population groups. International multi-database research facilitates comparisons across 
geographical areas and jurisdictions, increases statistical power to investigate small sub-populations 
or rare outcomes, permits early post-approval assessment of safety and effectiveness, and increases 
generalisability of results. Through bringing together international researchers in 
pharmacoepidemiology, NeuroGEN has the potential to be paradigm changing for observational 
research to inform evidence-based prescribing. The first focus of NeuroGEN will be to address 
evidence-gaps in treatment of chronic comorbidities in people with dementia.  
 
Key points:  
- Neurological and mental health disorders have a disproportionately large impact on global 
disease burden, but people with these disorders are often under-represented in randomized 
controlled trials (RCTs) and real-world evidence is lacking. 
- International multi-database research using administrative data and electronic medical records 
provides an opportunity to conduct large and generalizable observational studies to generate 
new evidence to inform prescribing. 
- NeuroGEN addresses evidence-gaps in treatment of neurological and mental health disorders 






1.1 The global burden of neurological and mental health disorders 
Neurological disorders such as cognitive disorders (including dementia), stroke and Parkinson’s 
disease are leading causes of dependence and disability worldwide [1, 2]. Dementia has a global 
annual cost of US $818 billion [3]. The prevalence of age-related neurodegenerative disorders, 
including dementia and Parkinson’s disease, is expected to double over the next 20 years [1]. It was 
estimated that 43.8 million people were living with dementia in 2016 [4], with 7.7 million new people 
being diagnosed every year [5].. Over 6 million people worldwide have Parkinson’s disease, and the 
prevalence has doubled over a generation [6].  The total global burden of stroke is increasing, and 
close to 6 million people die because of stroke each year [7]. 
 
Psychiatric (mental health) disorders affect approximately 4.4% of the world’s population at any one 
point in time with an estimated 300 million people directly affected by depression in 2015 [8]. It is 
estimated that mental health disorders may be contributing to one third of total years lived with 
disability, depression being the most common disorder [9]. 
 
Optimizing care and support through appropriate pharmacological and non-pharmacological 
management can reduce burden in people with neurological and/or mental health disorders, their 
families, health-care systems and society. 
 
1.2 Evidence-gaps in the treatment of people with neurological and mental health disorders 
Reducing the social and economic burden of neurological and mental health disorders, particularly 
dementia, is a global health priority [3]. The World Health Organization (WHO) Ministerial 
Conference on Global Action Against Dementia highlighted the need for research to determine and 
ensure the optimal use of pharmacological treatments for symptoms of dementia [3]. There are 
currently clear evidence gaps affecting the quality of medication use in certain vulnerable populations, 
such as those with dementia. For example, participants included in randomized controlled trials 
(RCTs) do not necessarily represent the characteristics of people prescribed medications in routine 
clinical practice. Older people with neurodegenerative disorders are often excluded from RCTs [10] 
resulting in a lack of evidence for medication safety and effectiveness. This is despite people with 
neurodegenerative disorders often experiencing high rates of multimorbidity and treatment with 
multiple medications [11, 12]. For example, few people with dementia were eligible to participate in 
the pivotal direct oral anticoagulant (DOAC) RCTs [13], despite a high prevalence of cardiovascular 
and cerebrovascular disease in this population [11]. In RCTs of acetylcholinesterase inhibitors, 




Specific evidence regarding the benefits and risks of medications in people with dementia is lacking 
[10], yet results of a recent nationwide study demonstrated that people with dementia were more 
likely to be exposed to polypharmacy (dispensed five or more medications) than people without 
dementia [15]. Insufficient evidence may lead to reliance on evidence extrapolated from other 
populations or settings, or prescribing decisions based on assumed benefits and risks. This could 
compound prescribing uncertainty, or lead to inappropriate prescription of guideline recommended 
medications for comorbid conditions. The United Kingdom (UK) primary care data suggest comorbid 
depression is diagnosed in 17%, 21%, 18% and 32% of people with coronary heart disease, stroke, 
diabetes and dementia, respectively [16]. Despite being highly prevalent, people with diagnosed 
depression are often excluded from RCTs related to management of these conditions.   
 
1.3 The role of administrative claims and electronic medical record data in central nervous 
system drug research  
The rapid increase in the availability of administrative and electronic medical record (EMR) data has 
resulted in new potential for ‘big data’ research in medication safety and effectiveness [10]. These 
data are collected from hospitals, primary care medical practices and pharmacies. Clinical registries 
have also been established in primary and secondary care, often with linkage to administrative data. 
High quality multi-database observational studies of such ‘big data’ enables comparisons across 
geographical areas and jurisdictions, an increase in statistical power to investigate small sub-
populations, rare outcomes, early post-approval assessment of safety and effectiveness, and an 
increased generalisability of findings.  
 
2 The Neurological and Mental Health Global Epidemiology Network (NeuroGEN)  
 
2.1 Description of NeuroGEN  
NeuroGEN (https://www.neurogen.hku.hk/) is an international ‘big data’ collaboration platform 
established at a multidisciplinary meeting of 30 researchers from eight international geographical 
regions in Hong Kong in October 2018 [17]. NeuroGEN evolved out of the PharmAlliance 
collaboration in pharmacoepidemiology between Monash University, University College London 
(UCL) and University of North Carolina at Chapel Hill (UNC). PharmAlliance is a strategic 
partnership for staff and students in the Universities’ Pharmacy Schools: Monash University Faculty 
of Pharmacy and Pharmaceutical Sciences, UCL School of Pharmacy and UNC Eshelman School of 
Pharmacy. PharmAlliance provides strategic seed funding for multi-institutional initiatives in 
research, practice and education. The funds are an investment from each School to support 
PharmAlliance activities. The purpose of the October 2018 meeting was to explore data available in 
different jurisdictions, identify the breadth of clinical and methodological expertise, and to set 
research priorities. Research priority setting involved identifying 29 topics, of which six were 
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prioritized highest. A second multidisciplinary meeting was held in London in August 2019 which 
included new member institutions and researchers. At this meeting respective research groups 
presented and discussed their progress in relation to the existing and new topics. A map of current 
member regions is presented in Figure 1. Initial seed funding provided by PharmAlliance has been 
supplemented by grants from the Victorian Medical Research Acceleration Fund, University College 
London (UCL) - Peking University Strategic Partnership Grant, and University of Hong Kong - UCL 
Strategic Partnership Grant and Research Grant Council of Hong Kong. Dementia Australia Research 
Foundation – Yulgilbar Innovation Grant was received to investigate guideline-recommended 
medication use in people with dementia and chronic comorbidities. This Four Continents For 
Dementia (4C4D) program involves Australia, Hong Kong, UK and United States (US). 
 
2.2 NeuroGEN member institutions and databases  
NeuroGEN facilitates access to a global network of administrative and medical record data for the 
purpose of conducting multi-database observational research with a focus on neurological and mental 
health. Collectively, data are available for an estimated 100 million people with and without 
neurological and mental health disorders. There are significant variations of local regulatory and 
ethical framework between different parts of the world, therefore, each NeuroGEN partner works with 
the relevant data custodians and ethics committees to comply with the local legal and ethical 
requirements. 
 
Data included in each of the databases are described in Table 1.  
 
2.2.1 Monash University, Australia 
Monash University’s Centre for Medicine Use and Safety (CMUS) comprises investigators in 
pharmacoepidemiology and clinical pharmacy. One of CMUS research priorities is to use 
administrative claims data to improve optimal use of medications, focussing on dementia and 
cardiovascular diseases [18, 19]. The primary data source is a 10% random sample of national 
dispensing data from Australia’s Pharmaceutical Benefits Scheme (PBS) covering 10% (≈2.5 million) 
of Australia’s population. This dataset is provided in a standard de-identified form by Services 
Australia by application. A newly established data source is Victorian-wide hospitalization database 
linked to the PBS, general medical practitioner data obtained through the Medicare Benefits Schedule 
(MBS), emergency department visits and mortality data. Victoria is the second most populous state in 
Australia with a population of 6.6 million. The linked Victorian data has been approved by all data 
custodians with a waiver of informed consent due to retrospective use of the data and that consent 
would not have been feasible to obtain. 
  
2.2.2 University of Hong Kong (HKU), Hong Kong 
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The HKU team has conducted multi-database pharmacoepidemiological studies using EMRs [20-22]. 
The primary source of data is the Clinical Data Analysis and Reporting System (CDARS) managed by 
the Hospital Authority (HA) in Hong Kong. The HA is the sole public-funded health care provider, 
whose primary, secondary and tertiary care services are accessible to all Hong Kong residents (>7 
million people). The CDARS includes records from all public hospitals, outpatient clinics and 
institutions under the HA. Research proposals are approved by the Research Ethics Committee under 
the HA. Informed patient consent is waived as the CDARS data used are de-identified. 
 
2.2.3 University College London (UCL), United Kingdom 
The UCL School of Pharmacy team’s research focusses on neurodegenerative and cardiovascular 
diseases, diabetes, child health and pregnancy [23-25]. The main source of data is the Health 
Improvement Network (THIN). THIN is a nationwide database that contains electronic primary care 
records from UK general practices for 15 million individuals [26]. THIN covers a 6% representative 
sample of the UK population. Multiple diagnoses and lifestyle variables recorded in THIN database 
including cardiovascular diseases, diabetes, obesity, smoking have been used and validated for 
pharmacoepidemiological research [27]. THIN is subject to the UK Data Protection Act 2018 and EU 
General Data Protection Regulation (GDPR). Data obtained has been anonymised and consent was 
previously collected by the general practices where patients can opt-out.  
 
2.2.4 University of Glasgow, United Kingdom 
The University of Glasgow has expertise on vascular neurological and cardiometabolic diseases [28-
30]. The primary source of data is the UK Biobank. The UK Biobank recruited 502,536 participants 
aged 39–72 years from the general population between 2007-2010. Participants attended one of 22 
assessment centres across England, Scotland, and Wales where they completed a self-administered 
questionnaire and face-to-face interview, and trained staff took a series of measurements including 
height, weight, and blood pressure. Mortality, hospitalization, and primary care consultations are 
available through data linkage. The UK Biobank has acquired explicit informed consent from all 
participants. 
 
2.2.5 University of Dundee, Scotland 
The Medicines Monitoring Unit (MEMO) Research group at the University of Dundee and Ninewells 
Hospital conducts observational studies [31, 32] and large decentralized clinical trials. MEMO 
currently have approximately 40,000 patients randomized into clinical trials. For 
pharmacoepidemiological studies MEMO researchers use data from the Information Services 
Division (ISD) of National Services Scotland, which is part of the public National Health Service 
(NHS). ISD provides health information, health intelligence, statistical services and advice that 
support the NHS with the goal to improve Scotland's health. The Service holds health-related data 
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which in some cases cover an individual from before birth (with the mother’s antenatal records) to 
their death. 
 
2.2.6 National Cheng Kung University (NCKU), Taiwan 
NCKU focuses on pharmacoepidemiology and big data research using claims data based on the 
National Health Insurance program in Taiwan [33, 34]. The National Health Insurance Database 
(NHID) was launched in 1995. The program covers over 99% of Taiwan’s population (25 million 
people) and enrolled more than 90% of hospitals and clinics. Ministry of Health and Welfare 
(MOHW) established a Health and Welfare Data Centre (HWDC), a data repository site that 
centralizes the NHID. The NHID includes medications, medical visits and procedures recorded in 
ambulatory, in-patient and emergency services. In addition, a multi-institutional electronic medical 
records database, the Chang Gung Research Database (CGRD) [35] containing clinical data such as 
pathological and laboratory results, is available to serve as external validation data for the NHID. The 
CGRD includes 1.3 million outpatients and 0.2 million inpatients in Taiwan [36, 37]. Due to 
retrospective nature of the provided data, informed consent is not required for either the NHID or the 
CGRD.  
 
2.2.7 SungKyunKwan University (SKKU), South Korea 
The Korean team focus on analyses of the National Health Insurance System (NHIS) claims database 
[38, 39] and multi-database studies. The NHIS in South Korea achieved universal coverage of the 
entire population in 1989. The database contains diagnostic and prescribing data for approximately 50 
million Koreans. The claims database includes data on each individual’s age, sex, diagnoses (ICD-10) 
and prescription medications. Information on prescription medications includes generic name, the date 
of prescription, duration, and route of administration. Due to retrospective nature of the provided data, 
informed consent is not required. 
 
2.2.8 University of Eastern Finland (UEF), Finland  
The Kuopio Research Centre of Geriatric Care focuses on pharmacoepidemiology in people with 
Alzheimer’s disease and Parkinson’s disease. This includes aetiological research, drug utilization 
studies and outcome studies [40, 41]. Primary sources of data are the nationwide MEDication use and 
ALZheimer’s disease (MEDALZ) study [42] on people with Alzheimer’s disease and the Finnish 
Medication and Parkinson’s disease (FINPARK) study on people with Parkinson’s disease [43]. Both 
studies include a matched cohort to facilitate comparisons to persons without these conditions and are 
derived from Finnish nation-wide databases including medication dispensing data, hospital discharge 
data and mortality data. The MEDALZ cohort includes incident cases of Alzheimer’s disease 
diagnosed from 2005-2011 and the FINPARK study includes incident cases of Parkinson’s disease 
diagnosed from1996-2015 with ongoing follow-up. Both MEDALZ and FINPARK data are used in 
11 
 
pseudonymised form. The research proposals were approved by the data custodians and according to 
Finnish legislation, other approvals or informed consent are not needed as the study is based on 
pseudonymized register data, and the participants are not contacted. 
 
2.2.9 Utrecht University (UU), the Netherlands 
UU’s Pharmacoepidemiology and Clinical Pharmacy group has a clinical, policy and methodological 
focus. The UU group has methodological expertise in methods to prevent and/or control for 
confounding, analysis of effect modification and conducting multi-database analysis. The primary 
data sources used for large pharmacoepidemiological studies include the Dutch PHARMO database 
(www.pharmo.nl) and the UK Clinical Practice Research Datalink (CPRD) [44]. CPRD is subject to 
the UK Data Protection Act 2018 and EU GDPR. Data obtained has been anonymised and consent 
was previously collected by the general practices where patients can opt-out. In PHARMO, patient 
information is deidentified and the requirement for individual consent is waived unless an intervention 
is planned. All use of the data requires approval by the independent Compliance Committee STIZON 
/ PHARMO Institute, in compliance with the Netherlands Personal Data Protection Act and Medical 
Treatment Contract Act. Data access is funded by the Utrecht Institute for Pharmaceutical Sciences. 
The UU group coordinate the European Research Network of Pharmacovigilance and 
Pharmacoepidemiology (EU PE&PV) and have developed novel methodologies for the conduct of 
multi-country, multi-database studies on variability of medication use and health outcomes [45-47]. 
 
2.2.10 Rutgers University, United States 
The Center for Health Services Research and Center of the Pharmacoepidemiology and Treatment 
Sciences at Rutgers’ Institute for Health are interdisciplinary groups with research focussing on the 
use and outcomes of medications across large, diverse usual-care populations in the US and other 
countries [48, 49]. Researchers at Rutgers have worked on studies particularly on the use and 
outcomes of central nervous system (CNS) drugs including opioid use disorders; use and outcomes of 
antipsychotics; treatment of adults with severe mental illness; use and safety of selective serotonin 
reuptake inhibitors in pregnant women; and psychotropic treatment for children. Main data sources 
include health insurance data from Center for Medicare and Medicaid services, which is updated 
annually: a 20% sample of Medicare patients representative of the US older people and people with 
end-stage renal diseases, and 45 State Medicaid Analytic Extracts (MAX) representative of low 
income population including pregnant women and children. According to the US Health Insurance 
Portability and Accountability Act of 1996 (HIPAA) privacy rules, informed consent was not required 
as the data are collected originally for insurance purposes, and secondary use of data for researchers is 
conducted without person identifiers.  
 




2.3.1 Case Study 1: Adherence and persistence to acetylcholinesterase inhibitors 
Acetylcholinesterase inhibitors (AChEIs) are the most widely prescribed medications for dementia, 
although efficacy [50, 51] and cost-effectiveness [51, 52] are modest. Non-adherence and non-
persistence reduce potential benefits, with a systematic review of five RCTs reporting discontinuation 
is associated with a significant decline in cognition and worsening of neuropsychiatric symptoms 
[53]. This highlights the importance of persistence in maximising benefit. This study will investigate 
adherence and persistence to AChEIs across the NeuroGEN partners. Australia, South Korea and 
Taiwan have analysed their respective data using a common study protocol. The study will utilize 
proportion of days covered to estimate adherence from medication dispensing and prescribing 
databases. Persistence will be estimated using a pre-specified gap of no dispensing or prescribing. 
This study will permit a comparison adherence and persistence using standardized definitions and 
methodology. This program of work is funded through the NHMRC Boosting Dementia Leadership 
Fellowship Scheme.  
 
2.3.2 Case Study 2: Predicting dementia and survival from cognitive footprints of 
electronic health records using machine learning 
Based on the ‘cognitive footprint’ of medical history, this population-based case-control study will 
aim to develop and validate an algorithm for predicting dementia using machine learning [54]. The 
algorithm will be trained using territory-wide EMRs from the CDARS in Hong Kong, and tested both 
locally and externally in other databases (e.g. the UK THIN and the Finnish MEDALZ). The CDARS 
currently hosts records from more than 70,000 people with dementia diagnoses between 2001 and 
2018. Potential protective/risk factors, which will be selected based on the cognitive footprint theory, 
will be modelled holistically. It is anticipated that the modelling will include analyses of diagnostic 
data, laboratory test results and the prescription of antidepressants, antipsychotics, statins and 
polypharmacy. Other than a set of Hong Kong-specific factors, a set of common factors that are 
shared by other databases will be identified to maximize interoperability. The subsequent common 
algorithm, to be derived from real-world data in Hong Kong, may then be suitable for embedding into 
other health information systems. Patients with a high risk or likelihood of dementia can be efficiently 
identified to permit targeting of risk-reduction programs. A secondary objective of this project is to 
estimate survival from the point of recorded diagnosis of dementia in Hong Kong, Canada, Finland, 
Germany, Korea, Taiwan, UK and US. This project will aggregate large population-scale data from 
different geographical regions. The project is ongoing and expected to complete by June, 2022. This 
project is funded by Research Grant Council of Hong Kong under the Early Career Scheme.  
 




In a meta-analysis of inception cohorts, Parkinson’s disease was associated with 1.5 times higher 
mortality [55]. The same meta-analysis demonstrated major heterogeneity in mortality ratios stratified 
by sex, and identified a need for further high-quality studies of mortality in Parkinson’s disease. 
Specifically, there is a lack of large-scale population-based inception cohorts with long-term follow-
up. This study will investigate survival of people with Parkinson’s disease following diagnosis, as 
well as possible geographical differences in mortality ratios and factors that predict higher mortality. 
The project is in its initiation phase. This project will be coordinated from Finland, and data from 
Finland, Hong Kong, Korea, Australia and the UK will be utilized. Additional countries will be 
included once confirmed with the corresponding investigators. Funding for this project has been 
applied. Once secured, the development of the common study protocol will commence.  
 
2.3.4 Case Study 4: Capacity building 
One of the objectives of NeuroGEN is capacity building and training the next generation of 
pharmacoepidemiologists. This is being achieved by providing opportunities to early career 
researchers, including PhD candidates and post-doctoral researchers. For example, PhD students from 
Monash University, Naresuan University (Thailand) and Princess Norah Bint Abdul Rahman 
University (Saudi Arabia) have conducted exchanges to UCL to conduct a pharmacoepidemiological 
studies [56-59].  Similarly, a PhD student from Monash University has conducted an exchange to 
HKU, and researchers from Utrecht University and UCL have conducted exchanges to Monash 
University. A bi-lateral exchange of post-doctoral researchers from University of Eastern Finland and 
Monash University has taken place [60]. These exchanges have been funded through Royal Golden 
Jubilee Ph.D. Program (Thailand) Newton Fund (UK), Saudi Arabian Ministry of Higher Education, 
the Australian Government Endeavour Fellowship Scheme, Monash Doctoral Program and NHMRC 
Boosting Dementia Leadership Scheme.   
 
3 Discussion and Future Directions 
 
3.1 Discussion 
Multi-national collaboration with data from multiple regions globally is a growing opportunity to 
conduct large generalizable observational studies that address research questions with international 
relevance. Use of a common protocol approach (CPA) and common data models (CDM) can facilitate 
large multi-database studies that address topics of international public health importance. NeuroGEN 
is currently using both the CPA and CDM. Although the CPA is more straightforward to implement, 
it requires close communication between investigators to ensure that all analyses are conducted 
consistently. A CDM is a sophisticated data platform supporting secondary use of data across multiple 
databases. The major advantage of CDM is that analyses are controlled by the use of standardized 
data structure, terminology, variable definitions and analytical program. Such distributed network 
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approach in which data partners maintain physical and operational control over the data in their 
existing environments also addresses data privacy issues across jurisdictions, because data are not 
shared. However, establishing the CDM requires a considerable investment of time and resources to 
convert native databases into the CDM. 
 
Existing examples of consortia with similar approach include the Asian Pharmacoepidemiology 
Network (AsPEN). AsPEN uses modified distributed networks with a common data structure across 
databases to allow single analytic programs to be used in each site [61]. Some NeuroGEN 
investigators are part of AsPEN and have established skills in multi-database studies. Another similar 
example is the Canadian Network for Observational Drug Effect Studies (CNODES) where databases 
across provinces in are analyses with the same approach [62].   
 
NeuroGEN investigators have created a simplified CDM based on the Observational Medical 
Outcomes Partnership (OMOP) CDM [63], containing all relevant information to conduct analyses for 
ongoing projects. A standalone analysis programme for each study will be developed based on the 
NeuroGEN CDM. Because the data structure and terminologies are identical among the converted 
databases, the analyses can be conducted in each home institution. Each site will generate a 
standardized results file which will then be collected by the coordinating site. Figure 2 presents the 
structure of the NeuroGEN CDM. Previous applications of similar conversions include for example 
paediatric use of prescription medications [64].  
 
Dementia Australia and Yulgilbar Foundation have funded the development of the CDM for four 
databases focussing on dementia research. The databases include the Australian linked health data, the 
US Medicare data, the UK THIN data and the Hong Kong CDARS data. The respective investigators 
are currently working together synchronising the databases into the CDM format to investigate the use 
of guideline-recommended medications for chronic comorbidities in people with and without 
dementia.    
 
3.2 Future directions 
 
The third NeuroGEN investigator meeting will be conducted in conjunction with the Asian 
Conference on Pharmacoepidemiology in Seoul, Korea in October, 2020. NeuroGEN is currently in 
discussion with partner research groups in other geographical regions, including Oceania and South 
America. The collaboration will continue to seek to address topics of global importance to better 






NeuroGEN is a recent initiative addressing medication use and outcomes in people with neurological 
and mental health disorders. NeuroGEN uses similar approach to other multi-database initiatives such 
as AsPEN and CNODES. However, NeuroGEN is the only global multi-database network addressing 
specifically issues arising in neurological and mental health field, and more widely in 
psychopharmacology. This will address significant evidence-gaps in this under-researched field.  
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Figure legends:  
Fig 1. Map of the NeuroGEN sites  
Fig 2. The proposed common data model structure for the NeuroGEN  
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Table 1. Summary of the content of the databases and their geographical locations  
Database 
name 











other clinical data  
Availability of 
lifestyle information 















diabetes or hip 
fracture  








item code, date of 
dispensing, 
quantity, strength 




N/A N/A Month, year and 



















conditions can be inferred 
from medication 
dispensings using the Rx-
Risk Index tool and 
prescriptions requiring 
specific diagnosis for 
reimbursement (authority)  







Finland  70,719 persons with 
AD and 282, 862 
comparison persons 
without AD (all 
community dwelling 
at the time of 
diagnosis); data 






Age, sex, hospital 
district, 
occupational 






onwards) data on 
e.g. ATC codes, 
medication 
names, pack size, 
dispensed amount 
-Hospital stays from 1972 
onwards: diagnoses (ICD-
8 until 1986, ICD-9 until 
1995, ICD-10 
-Procedure codes 
(Sairaalaliitto until 1995, 
NOMESCO since 1996) 
-Entitlement for special 
reimbursements for 
N/A institutionalizations, 
required level of 
assistance at 
hospital discharge 




in defined daily 
doses, strength, 
formulation, costs 
chronic conditions (since 
1972, national criteria 
consistent with 
international guidelines)  
-Detailed data on cancer 







Finland 21,683 persons with 
PD and 146,306 
comparison persons 
without PD (all 
community dwelling 
at the time of 
diagnosis); data 



















Hong Kong >7 million active, >11 
million total  
 
 
1995 - 2019 Sex, Year of 

























payment method  
Via linkage to Family 
Medicine records 















Hospital diagnoses and 
procedure (ICD-10-CD) 













4.2 million active 














Linkage to nationwide 
hospitalization database, 
in-patient hospital 
pharmacy database, (2 
million), GP database (2.5 
million) 














Scotland 5 million 2000-2019 Date of Birth, 
Gender, Ethnic 
Group, Marital 











dose duration are 
decoded. 
Hospital episodes of care 
data for acute conditions 
consisting of ICD and 
OPCS codes. There are 
also databases on 
maternity/ birth record/ 
child health/ cancer 
registration/ office for 
National Statistics death 
certification; data by ICD 
codes, birth, death, 
marriage. Via a separate 
system (Albasoft) access 
to GP data across nearly 
all practices in Scotland.  
A series of regional 
databases called SCI-
Store containing all 
labs data linked to the 
CHI number.  
PACS system, a 
Scottish wide 







calls databases.  
Via linkage to the 
National datasets for 
Lifestyle Alcohol 
Brief Interventions, 

























Taiwan 1.3 million 
















quantity, date of 
supply 
Hospital and clinic 
diagnoses and procedure  
ICD-9-CM/ ICD-10 
All laboratory data N/A Smoking, BMI, 
alcohol consumption 















quantity, date of 
supply 
Hospital and clinic 
diagnoses and procedure  
ICD-9-CM/ ICD-10 





UK  >4 million active, 13 





Age, sex, year of 
birth, registration 


















Test results (Type of 
test, result, normal 
range of result, unit of 
measure) 
Possible linkage to 
HES 
GP recorded BMI, 
smoking, alcohol 
consumption 
Date of death 












care data on 
prescription  
Self-report at baseline and 
linked mortality, 
hospitalization, and 




repeated measures in 
2012-13; additional 
Brain and heart 




Self-report lifestyle at 
baseline; small subset 
in repeated 
measurements 




from linked primary 
care data 







UK 4.4 million 
active, >11.3 million 
total patients meeting 
quality criteria  
Pre-2000 - 
2019 
Age, sex, month 
and year of birth, 
registration status, 








(date of treatment, 
quantity, duration, 
daily dose) 
Primary care clinical data, 
referral data, 
immunization data 
(READ codes)  
Test results (Type of 
test, result, normal 
range of result, unit of 
measure)  




GP recorded BMI, 
smoking, alcohol 
consumption 
Date of death 
(possible 




















Inpatient data ICD-9-CM/ 
ICD-10 codes for 


















Date of birth, sex, 
















Inpatient, outpatient and 
long-term care claims 
with ICD-9-CM/ICD-10-
CM codes for diagnoses 
and procedures 
Inpatient, outpatient 





Long-term care and 
diagnostic codes for 
palliative care, drug 
overdose, 
emergency visits 
N/A National Death 
Index date and 
ICD-10 cause of 
death codes for 
2001-2007 
Abbreviations: PBS Pharmaceutical Benefits Scheme; ICD International Classification of Diseases; N/A not applicable; MEDALZ MEDication use and ALZheimer's disease; AD Alzheimer’s disease; ATC Anatomical 
Therapeutic Classification; NOMESCO Nordic Medico-Statistical Committee; FINPARK Finnish Medication and Parkinson's disease; PD Parkinson’s disease; GP general practitioner; GMC General Medical Council; 
NHS National Health Service; UCPN Unique Care Pathway Number; PIS Prescribing Information System; OPCS Office of Population Censuses and Surveys; SCI Scottish Care Information; CHI Community Health 
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Index; PACS picture archiving and communication system; BMI Body Mass Index; UK United Kingdom; BNF British National Formulary; MRI Magnetic resonance imaging; HES Hospital Episode Statistics; ONS 
Office for National Statistics; US United States; HCPCS Healthcare Common Procedure Coding System; CPT Current Procedural Terminology 
 
 
